Overview
I am a physician-scientist with a background in medical oncology and neuro-oncology, with affiliations to multiple departments, research, and training programs at Duke.
I lead a Tumor Immunology Lab where we use various wet and dry lab techniques to understand the interactions between tumors and the immune system. Our goal is to identify vulnerabilities that can be targeted for novel therapies.
I serve as the Deputy Director of the Center for Cancer Immunotherapy at the Duke Cancer Institute where we are tasked to facilitate clinical research and translate promising discoveries made by scientists across various departments and cancer types at Duke, particularly in the field of immune and T cell-based therapies.
My team and our laboratory operate in an environment that enables the transition from bench-side basic scientific discoveries to clinical trials, and back to the bench ensuring the evaluation of new treatments for cancer patients.
Current Appointments & Affiliations
In the News
View All News
Recent Publications
The promise of TIL therapy for glioblastoma.
Journal Article Trends Cancer · November 13, 2025 Tumor-infiltrating lymphocyte (TIL) therapy has demonstrated efficacy in refractory melanoma and durable responses in lung cancer. Glioblastoma presents distinct challenges for immunotherapy, including profound tumor heterogeneity, low T cell infiltration, ... Full text Link to item CiteClinical trial of feasibility for mindfulness intervention for patients with newly diagnosed high grade glioma.
Journal Article J Neurooncol · November 5, 2025 PURPOSE: With a bleak prognosis for malignant glioma, maintaining quality of life (QoL) and decreasing distress are essential in patient clinical care. Mindfulness meditation is a mind-body therapy that is being investigated as a non-pharmacological strate ... Full text Link to item CiteA surgical window of opportunity trial evaluating the effect of the PCSK9 inhibitor evolocumab on tumoral MHC-I expression and CD8+ infiltration in glioma.
Journal Article Sci Rep · October 23, 2025 Many cancers evade immunosurveillance by downregulating surface major histocompatibility class (MHC)-I. Proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes MHC-I degradation and is elevated in glioma. Evolocumab is a clinically approved PCSK9 in ... Full text Link to item CiteRecent Grants
McCain/Bayh Glioblastoma Consortium
Clinical TrialCo-Project Leader · Awarded by Department of Defense · 2025 - 2029A Phase 3, open-label, randomized 2-arm study comparing the clinical efficacy and safety of niraparib with temozolomide in adult participants with newly-diagnosed, MGMT unmethylated glioblastoma
Clinical TrialPrincipal Investigator · Awarded by NeuroTrials, LLC · 2025 - 2029Glioblastoma Immunotherapy Advancement with Nivolumab and Relatlimab
Clinical TrialPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2024 - 2029View All Grants